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At a glance commentary 
Scientific knowledge on the subject 
Respiratory virus infections are associated with COPD exacerbations but a causative 
relationship has not been established and mechanisms of virus-associated 
exacerbations are undetermined.  
 
What this study adds to the field 
We report that experimental rhinovirus infection in COPD subjects reproduced the 
clinical, physiologic and inflammatory features of COPD exacerbations and 
implicates neutrophilic inflammation and impaired interferon production as important 
mechanisms of virus-induced COPD exacerbations. 
 
This article has an online data supplement, which is accessible from this issue's table 
of content online at www.atsjournals.org 
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Abstract 
Rationale: Respiratory virus infections are associated with COPD exacerbations but a 
causative relationship is not proven and mechanisms are poorly understood. Studies of 
naturally occurring exacerbations are difficult and have yielded little mechanistic 
insight. We hypothesized that experimental rhinovirus infection in COPD subjects 
would reproduce the features of naturally occurring COPD exacerbations and is a 
valid model of COPD exacerbations.  
Objectives: To evaluate experimental rhinovirus infection as a model of COPD 
exacerbation and investigate the mechanisms of virus-induced exacerbations 
Methods: We used experimental rhinovirus infection in 13 subjects with COPD and 
13 non-obstructed controls to investigate clinical, physiologic pathologic and anti-
viral responses and relationships between virus load and these outcomes. 
Measurements and Main Results: Clinical data, inflammatory mediators in blood, 
sputum and bronchoalveolar lavage and viral load in nasal lavage, sputum and 
bronchoalveolar lavage were measured at baseline and following infection with 
rhinovirus 16. Following rhinovirus infection COPD subjects developed lower 
respiratory symptoms, airflow obstruction and systemic and airways inflammation 
that were greater and more prolonged compared to the control group. Neutrophil 
markers in sputum related to clinical outcomes and virus load correlated with 
inflammatory markers. Virus load was higher and interferon production by 
bronchoalveolar lavage cells impaired in the COPD subjects.  
 
Conclusions: We have developed a new model of COPD exacerbation that strongly 
supports a causal relationship between rhinovirus infection and COPD exacerbations. 
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Impaired interferon production and neutrophilic inflammation may be important 
mechanisms in virus-induced COPD exacerbations. 
 
Number of words in abstract: 236 
 
Key words: disease exacerbation, respiratory tract infections 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a growing global epidemic and its 
prevalence is expected to increase markedly in the future (1). The major cause of 
morbidity and mortality in COPD are acute exacerbations that are associated with 
impaired quality of life (2;3), accelerated loss of lung function (4) and enormous 
health care costs (5). Current therapies are only partially effective, have significant 
side effects and may not address the true underlying mechanisms (6;7). Exacerbations 
are associated with increased airways inflammation; however studies of cellular and 
molecular inflammatory mediators in COPD exacerbations have yielded conflicting 
results (8-13). This is due to factors such as heterogeneous exacerbation aetiologies, 
variations in time from onset to investigation, effects of treatment and difficulties with 
both baseline and acute sampling that are inherent in studies of naturally occurring 
exacerbations. Respiratory virus infections, most commonly rhinoviruses, can be 
detected in COPD exacerbations but detection rates vary (11;13-16) and viruses are 
found in stable COPD also (14;17). Therefore a causal relationship between 
respiratory virus infection and acute exacerbations in COPD patients has not been 
established. In healthy individuals rhinovirus infections cause a predominantly upper 
respiratory tract illness with little evidence of lower respiratory tract involvement 
(18;19). In COPD the association of rhinovirus infection with exacerbations is 
suggestive of increased susceptibility to infection and lower respiratory tract 
involvement, however this has not been proven and mechanisms involved are 
unknown.  
Experimental rhinovirus infection studies in asthma have yielded important insights 
into disease mechanisms, and have identified candidates for development of new 
therapies (19-21). No similar experimental model has existed for studying 
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mechanisms of COPD exacerbations. Such a model could overcome the sources of 
variation in naturally occurring exacerbations and provide a tool with which to 
investigate the relationship between virus infection and COPD exacerbations.  We 
previously reported an uncontrolled pilot study investigating experimental infection 
with low dose rhinovirus in 4 COPD patients; infection induced symptoms consistent 
with COPD exacerbation and no adverse safety signal was observed (22). In the 
present study we aimed to demonstrate that this model is valid in larger numbers of 
COPD subjects and perform intensive lower airway sampling to investigate airways 
inflammation in virus-induced COPD exacerbations. In addition we also infected a 
group of smokers without airflow obstruction to investigate mechanisms of 
susceptibility to virus infection in COPD. Here we report that rhinovirus infection 
induces the symptomatic, physiologic and inflammatory features that have been 
reported in naturally occurring exacerbations, and that infection is associated with 
neutrophilic inflammation and deficient production of interferon-β in COPD subjects. 
Some of the results of this study have been previously reported in abstract form (23-
25) 
 
 
Methods 
Participants 
Subjects were recruited from Imperial College Healthcare NHS Trust (St Mary’s 
Hospital), the Royal Brompton Hospital, local General Practices and by 
advertisement. Ethical approval was obtained from the Local Research Ethics 
Committee (study number 00/BA/459E) and informed consent obtained from all 
subjects. The inclusion/exclusion criteria for the COPD subjects were identical to 
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those used in our pilot study (22) and a group of control subjects with a similar 
smoking history but with normal lung function was also recruited (Supplementary 
Table 1).  
 
Study design and experimental infection protocol 
We aimed to recruit and infect 13 subjects in each group as such numbers had yielded 
significant findings in similar studies in asthma (19;20;26). At initial screening visits 
suitability for the study was assessed, informed consent obtained and serum 
neutralising antibodies to rhinovirus 16 measured (19). For those entering the study 
baseline clinical sampling was performed 1–4 weeks prior to virus inoculation, which 
was on study day 0. Subjects were seen daily on the 9 days immediately post-
inoculation, on days 12 and 15 and then weekly until 6 weeks post-inoculation. The 
timeline for clinical measurements and sampling is outlined in Supplementary Table 
2. 
 
Clinical procedures 
Upper and lower respiratory symptom scores  
Daily diary cards of upper and lower respiratory symptoms were commenced at 
screening and continued until 6 weeks post-inoculation. The symptom scores and cold 
and exacerbation criteria were the same as those used in the pilot study and are 
described in the Supplementary Methods and Supplementary Table 3.  
Pulmonary function 
Spirometry was performed on a Micromedical MicroLab spirometer (MicroMedical, 
Rochester, UK) according to British Thoracic Society guidelines (27) before and 15 
minutes after administration of 200µg salbutamol via metered dose inhaler and large 
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volume spacer for pre- and post-bronchodilator values. Carbon monoxide diffusion 
capacity corrected for alveolar volume (KCO) was measured on a Vmax 229 (Viasys) 
in the pulmonary function laboratory of St Mary’s Hospital, Imperial College 
Healthcare NHS Trust according to established protocols.  
Virus inoculation 
Details regarding the preparation and safety testing of the rhinovirus 16 inoculum 
used in this study have been published (28). 10 TCID50 of the virus was diluted in a 
total volume of 1 mL of 0.9% saline and inoculated in both nostrils using an atomizer 
(No. 286; DeVilbiss Co., Heston UK).  
 
Nasal lavage, induced sputum and bronchoscopy 
Sputum was induced by inhalations of hypertonic saline according to European 
Respiratory Society guidelines (29) and processed according to standard protocols 
(30). Bronchoscopies were performed according to British Thoracic Society 
guidelines for research bronchoscopies (31). Details of nasal lavage, sputum and 
bronchoalveolar lavage (BAL) processing are provided in the Supplementary 
Material. 
 
Virus detection 
Detection of rhinovirus and other respiratory viruses was performed using polymerase 
change reactions (PCR) according to previously established protocols (19). Infection 
with viruses other than rhinoviruses was excluded by testing nasal lavage with PCR. 
Details are provided in the Supplementary Methods.  
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Inflammatory mediators 
Interleukin (IL)-6, IL-8, neutrophil elastase and tumour necrosis factor-alpha (TNF)-α 
were measured in sputum and BAL supernatants. Interferons-beta (IFN-β), alpha 
(IFN-α) and lambda (IFN-λ) and IFN-gamma-inducible protein 10 (CXCL10) were 
measured in supernatants from BAL cells cultured ex vivo. All soluble mediators were 
measured using enzyme-linked immunosorbent assays (ELISA) - details are provided 
in the Supplementary Methods. Serum CRP and peripheral blood cell counts were 
measured in the Clinical Biochemistry and Haematology laboratories of St Mary’s 
Hospital, Imperial College Healthcare NHS Trust.  
 
Statistical analysis 
Data are presented as mean (±SEM) values for normally distributed data or median 
(interquartile range) for non-parametric data. Changes from baseline were analysed 
with repeated measures ANOVA (Friedman test for non-parametric data) and, if 
significant, paired t-tests or Wilcoxon matched pairs test. Differences between groups 
were analyzed by using unpaired t-tests or Mann-Whitney tests. Correlations between 
data sets were examined using Pearson’s correlation and Spearman's rank correlation 
coefficient. Differences were considered significant for all statistical tests at P values 
of less than 0.05. All reported P values are two-sided. Analysis was performed using 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego USA). 
 
 
Results 
Thirteen subjects were recruited in each group and inoculated with low dose 
rhinovirus 16. In 3/26 subjects (2 COPD and 1 control) rhinovirus was not detected 
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after inoculation so they were excluded from further analysis. The clinical 
characteristics of the 23 successfully infected subjects included in the data analysis 
are shown in Table 1. Following inoculation there were no adverse events and no 
subjects withdrew from the study or required corticosteroids, antibiotics or hospital 
admission.  
Clinical responses to rhinovirus infection  
Upper respiratory symptoms 
Twenty-one of the 23 subjects fulfilled the symptom criteria for a clinical cold (see 
Supplementary Material). The remaining 2 subjects (1 in each group) had the 
subjective sensation of a cold but did not fulfil the other 2 symptom criteria however 
both had virologic evidence of rhinovirus infection. Daily upper respiratory symptom 
scores were significantly increased above baseline in the COPD group on days 2–14 
post-inoculation and on days 1–12 in the controls (Figure 1A) and were significantly 
greater in the COPD group compared to the controls on days 13–16.  
Lower respiratory symptoms 
Ten of the 11 infected COPD subjects fulfilled the symptom criteria for a COPD 
exacerbation. Daily total lower respiratory symptom scores were increased 
significantly over baseline on days 5–19 in the COPD group and on days 3–9 in the 
controls (Figure 1B). Daily lower respiratory symptoms were significantly greater in 
the COPD group compared to controls on days 11, 14, 27, 29, 34 and 35. When the 
individual symptoms were analysed daily breathlessness scores were increased over 
baseline on days 5–12 in the COPD group, while breathlessness did not increase 
significantly in the controls (Figure 1C). Daily breathlessness scores were 
significantly higher in the COPD group than in controls on days 5 through 25, except 
days 14 and 15.  
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Lung function 
Post-bronchodilator peak expiratory flow (PEF) fell significantly from baseline in the 
COPD group but no significant reductions were observed in the controls (Figure 1D) 
and on day 28 PEF was significantly lower in the COPD group compared to the 
controls (92.36±2.23% vs. 102.5±2.95, P=0.014). KCO (% baseline) on day 12 fell 
significantly from baseline in the COPD group (100 vs. 93.82±1.52, P=0.0027) but 
not in the controls (100 vs. 96.18±2.15, P=0.1) There were small falls from baseline 
in Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and 
the FEV1/FVC ratio that were of similar magnitude in both groups but were not 
statistically significant. 
 
Inflammatory responses to rhinovirus infection  
Blood 
There was a significant increase in blood neutrophils on day 15 compared to baseline 
in the COPD group; however no significant change in blood cell counts were 
observed in the control group. There were significant increases from baseline in serum 
C-reactive protein (CRP) on day 5 in both the COPD and control groups, while CRP 
was increased above baseline on day 9 only in the COPD group. There were no 
significant differences between groups in blood neutrophils or CRP (Supplementary 
Table 4). 
Sputum 
Adequate sputum samples (<20% squamous cells) were obtained from 10/11 COPD 
subjects and 11/12 controls. Percent sputum neutrophils increased significantly over 
baseline on days 5, 9, 12 and 15 in the COPD subjects, while there was no significant 
increase in sputum neutrophils in the controls (Figure 2A). Sputum neutrophil 
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percentages were significantly higher in the COPD group compared to the controls on 
days 5, 12, 15, 21 and 28. Sputum supernatant neutrophil elastase levels were 
significantly increased over baseline on days 9 and 15 and IL-8 levels on day 9 in the 
COPD subjects, while no significant increases were observed in the control subjects 
(Figures 2B and 2C). Sputum neutrophil elastase levels were significantly higher in 
COPD subjects compared to controls on days 9, 12 and 15. There were no statistically 
significant changes from baseline in either group in sputum supernatant levels of IL-6 
or TNF-α and no statistically significant differences between groups in sputum IL-6, 
IL-8 or TNF-α (Supplementary Table 4). 
BAL 
BAL was not obtained from 1 COPD subject at the infection bronchoscopy. There 
was a significant increase in BAL lymphocyte percentage from baseline to infection 
(Figure 2D) in the COPD group but not in the controls. There was no significant 
change between baseline and infection in BAL neutrophils, however BAL neutrophils 
at infection were significantly higher in the COPD group compared to the controls 
(Figure 2E). There was a significant increase from baseline to infection in BAL fluid 
IL-6 levels in the COPD group, but not in the controls, while BAL fluid neutrophil 
elastase, IL-8 and TNF-α did not increase significantly in either group. There were no 
significant differences between groups in BAL lymphocytes or BAL fluid levels of 
neutrophil elastase, IL-6, IL-8 or TNF-α (Supplementary Table 5). 
 
Virologic responses  
Infection with rhinovirus was confirmed by PCR in all 23 subjects. Following 
inoculation with rhinovirus 16, nasal lavage virus load (Log10 copies/mL) showed a 
rapid rise in both groups commencing ~48 hours after inoculation in a manner typical 
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of an acute infection (Figure 3A and Supplementary Table 6). Virus load peaked on 
days 4–8 in nasal lavage and in sputum on day 5, remaining significantly elevated 
over baseline up to day 15. Nasal lavage virus load was 1–2 Logs higher in the COPD 
group compared to the controls from days 3–12, and this difference was statistically 
significant on day 6. Sputum virus load was also 1–3 Logs higher in the COPD group 
on days 5 and 9 but this was not statistically significant (Figure 3B). Peak virus load 
was 1–2 Logs but non-significantly higher in the COPD group in nasal lavage 
(7.0±0.58, 5.85±0.47; P=0.14), sputum (9.44±0.95, 8.53±0.34; P=0.41) and BAL 
(6.26±0.63, 5.09±0.24; P=0.14).  
 
Relationships between virus load, inflammatory markers and clinical outcomes 
In the COPD subjects there were strong correlations between sputum neutrophil 
elastase levels and clinical outcomes: peak increase in sputum neutrophil elastase 
correlated with peak total lower respiratory symptom scores (r=0.62, P=0.044), peak 
breathlessness scores (r=0.62, P=0.042) and with maximum fall in PEF (r=-0.8, 
P=0.003) and FEV1/FVC ratio (r=-0.68, P=0.021). Peak sputum neutrophil numbers 
also correlated with fall in PEF (r=-0.77, P=0.0092). 
Peak sputum virus load in COPD subjects correlated positively with each of peak 
serum CRP levels (r=0.89, P=0.0002), peak sputum neutrophil numbers (r=0.74, 
P=0.009) and peak sputum supernatant levels of IL-8 (r=0.81, P=0.0016), IL-6 
(r=0.61, P=0.046), neutrophil elastase (r=0.69, P=0.018) and TNF-α (r=0.63, 
P=0.037) (Figure 4). BAL virus load in COPD subjects correlated positively with 
BAL fluid levels of neutrophil elastase (r=0.84, P=0.0024), IL-8 (r=0.65, P=0.042) 
and IL-6 (r=0.67, P=0.034). There were no significant correlations between virus load 
and inflammatory markers in the controls. 
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Impaired interferon production in COPD subjects 
Sufficient BAL cells for ex vivo cultures were obtained at the baseline bronchoscopy 
from 10 controls and 7 COPD subjects. These cells were incubated with live 
rhinovirus, medium alone or virus inoculum from which virus had been removed by 
molecular weight filtration (20). In BAL cells infected with live rhinovirus induction 
of both IFN-α and IFN-λ release into supernatants was impaired by ~50% in the 
COPD group but differences between groups were not statistically significant (Figures 
5A and 5B). In BAL cells from the controls rhinovirus infection induced significant 
increases in IFN-β compared to filtered virus but not in the COPD subjects and IFN-β 
levels induced by infection were significantly higher in the controls compared to the 
COPD group (Figure 5C). The deficient IFN induction by rhinovirus in COPD was 
also accompanied by deficient induction of the interferon stimulated gene (ISG) 
CXCL10. Rhinovirus infection induced significant up-regulation of CXCL10 protein 
levels in BAL supernatants in the controls (1411±777.3 pg/mL vs. 8413±1707, 
P=0.0022) but not in the COPD group (379.1±150.3 vs. 6040±4069, P=0.26). Virus 
infection induced significant up-regulation of IL-8 in BAL cells from both groups 
(data not shown). 
 
 
Discussion 
In this study we report that experimental rhinovirus infection in COPD subjects 
induced symptoms, airflow obstruction and neutrophilic inflammation of significant 
severity and duration. Virus load in sputum correlated strongly with inflammatory 
markers and IFN-β production by airway macrophages was impaired in COPD. These 
data suggest that experimental rhinovirus infection is a valid human model of COPD 
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exacerbations and a novel tool with which to further investigate mechanisms of virus-
induced exacerbations. 
There is no universally agreed definition of a COPD exacerbation, however, 
exacerbations are normally defined by acute increases in lower respiratory symptoms 
above normal daily variability (5) and are associated with increased airflow 
obstruction (32). Following rhinovirus infection COPD subjects reported significantly 
increased lower respiratory symptoms above their baseline symptoms and 10/11 
fulfilled the predetermined criteria for an acute exacerbation that was based on 
accepted criteria from studies of naturally occurring exacerbations (2;33-35). The 
controls also developed lower respiratory symptoms but these were of lesser severity 
and duration than the COPD subjects. Only the COPD subjects developed significant 
increases in breathlessness, suggesting this is the key symptom that differentiates a 
COPD exacerbation from an uncomplicated acute viral bronchitis. This is supported 
by data from naturally occurring rhinovirus infections (36). Furthermore we 
documented increased airflow obstruction in COPD subjects with falls from baseline 
in PEF of ~10%, observations that are consistent with studies of naturally occurring 
exacerbations (32;37). There was a temporal relationship between virus detection in 
the respiratory tract and the onset of symptoms and airflow obstruction, and virus 
clearance was followed by clinical recovery. Therefore this study provides the first 
direct experimental evidence that rhinovirus infection precipitates the symptomatic 
and physiological changes in COPD that define an acute exacerbation.  
The nature of the inflammatory response in COPD exacerbations remains 
controversial and there is no single cellular or molecular inflammatory marker that 
defines an exacerbation (9;11;38). Both neutrophilic and eosinophilic inflammation 
has been reported related to virus infection (11) but other studies have reported that 
Page 16 of 31
14 
 
virus infection is not associated with pulmonary or systemic inflammatory markers 
(12;13;39) and therefore the relationship between virus infection and airway 
inflammation in COPD exacerbations is unclear. We report that rhinovirus infection 
was temporally associated with a significant and sustained neutrophil influx and 
increased levels of neutrophil elastase and IL-8 in sputum in COPD subjects. There 
were strong correlations between sputum neutrophil elastase levels and severity of 
symptoms and airflow obstruction exclusively in COPD subjects. Neutrophil elastase 
has been related to exacerbation severity in bacterial exacerbations (40) and our data 
implicates it as a key mediator of virus-induced exacerbations also. In addition virus 
load correlated significantly with neutrophil numbers and inflammatory mediators in 
serum, sputum and BAL. In BAL lymphocytes and IL-6 were both also significantly 
increased after rhinovirus infection and further studies will be needed to investigate 
the importance of these and other inflammatory cells and mediators in COPD 
exacerbations. Therefore these data are the first to directly link virus infection of the 
lower respiratory tract to lower airways inflammation in COPD and strongly support a 
causative role for virus infection. 
It is not known whether COPD are more susceptible to respiratory virus infections. 
We demonstrated increased severity and duration of respiratory symptoms, greater 
lung function impairment and increased airway inflammation in COPD subjects 
compared to smokers without airflow obstruction. Daily and peak virus loads in each 
of nasal lavage, sputum and BAL were consistently 1–3 Logs higher in COPD 
subjects, and although these differences were not statistically significant other than on 
day 6 the consistency of these findings throughout the acute infection and in 3 
different clinical samples adds weight to their validity. These data confirm increased 
susceptibility to rhinovirus infection in COPD. A key constituent of innate immune 
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responses to virus infection is production of interferons by infected cells. We have 
previously shown that IFN-β and IFN-λ production is impaired in asthma (20;21) and 
herein we report impaired BAL cell production of IFN-β in response to virus infection 
in COPD subjects and trends to reduced IFN-α and IFN-λ. As IFN-β is an early and 
essential component of anti-rhinoviral immunity (21) this may be an important 
mechanism underlying increased severity of rhinovirus infection in COPD. A recent 
report of in vitro rhinovirus infection of epithelial cells from COPD patients reported 
higher virus load but no differences in interferon production (41). Therefore other 
mechanisms may also be involved in susceptibility to virus infection in COPD. 
We have established experimental rhinovirus infection is a valid model of COPD 
exacerbation and therefore this provides an important new tool for studying 
exacerbations. This model has major advantages as it permits investigations of 
exacerbations in a controlled manner with a single aetiogical agent, and facilitates 
longitudinal sampling allowing investigation of temporal and quantitative 
relationships between virus infection, inflammatory mediators and biological and 
physiological markers in a manner not possible with cross-sectional studies of 
naturally occurring exacerbations. The evidence we provide linking rhinovirus 
infection to COPD exacerbations should stimulate research into both existing and 
novel antiviral therapies as potential therapies in COPD (42). Therapies targeting 
neutrophilic inflammation (43) and neutrophil elastase inhibitors (44) or augmentation 
of interferon-β may also have potential in treatment or prevention of COPD 
exacerbations. This model will also be a useful tool to assist in testing efficacy of new 
therapies.  
Limitations of our study include the relatively small numbers of subjects and the 
higher mean age of the COPD group. As this is the first study to perform experimental 
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rhinovirus infection in COPD subjects and smokers there was no data on which to 
base power calculations. The data from this study can be used to design further 
experimental infection studies and it is possible that with larger subject numbers 
statistically significant differences in virus load and IFN-α and IFN-λ will become 
apparent. We examined the data for correlations between age and clinical, 
inflammatory and virologic outcomes and interferon production and none were found. 
However further studies are required to replicate these findings in greater numbers of 
subjects and with subject groups more closely matched for age.   
In conclusion we have shown that experimental rhinovirus infection induces the 
clinical features of COPD exacerbations, that neutrophilic airway inflammation is an 
important mechanism of virus-induced exacerbations and that deficient production of 
IFN-β may contribute to increased susceptibility to virus infection in COPD. This 
model will facilitate research into mechanisms of COPD exacerbations thereby 
boosting efforts to develop new approaches for the prevention and treatment of 
exacerbations of COPD.  
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Figure Legends 
Figure 1. Symptom scores and lung function during experimental rhinovirus infection. 
The time course for daily symptom scores are shown for total daily upper respiratory 
symptoms (Panel A), total daily lower respiratory symptoms (Panel B) and 
breathlessness (Panel C). Panel D shows the time course of post-bronchodilator peak 
expiratory flow as percentage of baseline (all mean±SEM). *P<0.05 vs. baseline, 
**P<0.01 vs. baseline, †P<0.05 COPD vs. controls, ††P<0.01 COPD vs. controls, 
†††P<0.001 COPD vs. controls.  
 
Figure 2. Airway inflammatory cells and soluble mediators during experimental 
rhinovirus infection. The time course of percentage neutrophils (mean±SEM) (Panel 
A), neutrophil elastase (median (IQR) (Panel B) and IL-8 (mean±SEM) (Panel C) in 
induced sputum are shown. Panels D and E show lymphocytes and neutrophils in 
bronchoalveolar lavage (both mean±SEM). *P<0.05 vs. baseline, **P<0.01 vs. 
baseline, †P<0.05 COPD vs. controls, ††P<0.01 COPD vs. controls.  
 
Figure 3. Virus load in nasal lavage and sputum. The time course of virus load 
measured with qPCR is shown in nasal lavage (Panel A) and sputum (Panel B) (both 
mean±SEM). *P<0.05 vs. baseline, **P<0.01 vs. baseline, ***P<0.01 vs. baseline, 
†P<0.05 COPD vs. controls.  
 
Figure 4. Correlations between sputum virus load and inflammatory markers. 
Relationships between sputum virus load and inflammatory markers in COPD 
subjects are shown. There were significant correlations between peak sputum virus 
load and peak serum C-reactive protein (Panel A), peak sputum neutrophils (Panel B), 
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peak sputum IL-8 (Panel C), peak sputum neutrophil elastase (Panel D), peak sputum 
IL-6 (Panel E) and peak sputum TNF-α (Panel F).  
 
Figure 5. Interferon responses in BAL cells. Cells obtained by BAL were infected ex 
vivo with rhinovirus 16 and interferon-α (Panel A), interferon-λ (Panel B) and   
interferon-β (Panel C) measured in supernatants 48 hours post-infection (all 
mean±SEM). *P<0.05 vs. filtered virus, **P<0.01 vs. filtered virus, †P<0.05 COPD 
vs. controls. Comparisons between COPD and control groups are indicated above the 
relevant brackets.  
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Tables 
Subject 
characteristics 
COPD  
(N=11) 
Controls  
(N=12) 
Unpaired t 
test 
Age 
(years) 59.6 [47 – 70] 48.5 [40 – 58] P=0.0021 
Sex (M/F) 6/5 6/6 P=NS 
Smoking history 
(pack-years) 48 [20 – 109] 34.8 [20 – 60] P=NS 
Current smokers  
(no.) 8 9 P=NS 
FEV1 
(litres) 1.94 [1.23 – 2.7] 3.58 [2.8 –  4.76] P<0.0001 
FEV1 
(% of predicted 
normal value) 
69.73 [62 – 78] 109.5 [90 – 128] P<0.0001 
FEV1/FVC 
(%) 55.55 [39 – 69] 80.33 [73 – 86] P<0.0001 
COPD denotes chronic obstructive pulmonary disease, FEV1 forced expiratory 
volume in one second, FVC forced vital capacity, pack-years the number of 
cigarettes smoked per day multiplied by the number of years of smoking. Values 
are mean (range). 
 
 
Table 1. Clinical characteristics of the 23 study subjects included in the study. 
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